Investor contact
For investor related questions, please email
investors@aclaristx.com
Media contact
& resources »

Press Releases

Press Releases

November 7, 2019
Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
October 31, 2019
Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
October 24, 2019
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
October 10, 2019
Aclaris Therapeutics Announces Divestiture of RHOFADE®
October 8, 2019
Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%
September 17, 2019
Aclaris Therapeutics to Hold R&D Day
September 16, 2019
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
September 5, 2019
Aclaris Therapeutics Announces New Strategic Direction
August 8, 2019
Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments
August 1, 2019
Aclaris Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
July 30, 2019
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
July 9, 2019
Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1%
July 3, 2019
Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors
June 26, 2019
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
June 17, 2019
Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)
June 14, 2019
Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference
May 24, 2019
Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
May 8, 2019
Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments
May 1, 2019
Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
April 25, 2019
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis
April 24, 2019
Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata
March 27, 2019
Aclaris Therapeutics to Attend Upcoming Investor Conference
March 18, 2019
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments
March 8, 2019
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019
February 28, 2019
Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg
February 19, 2019
Aclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology
January 2, 2019
Aclaris Therapeutics to Attend Upcoming Investor Conferences
Load More »